Link: https://links.sgx.com/1.0.0/corporate-announcements/YU3QQ54PMR22IQMC/68593c23f6bfbecc6b09a4d81d940134799ee3090bd5b39df3b02c7e3e4d90c4

Summary:

• Revenue surged to S$674,000 for 1H 2025 (up more than 100% from S$89,000 in 1H 2024), primarily due to the acquisition of Jas Medical Screening Centre.

• Net loss after tax was S$599,000 for 1H 2025, compared to a loss of S$319,000 in 1H 2024.

• Other income declined sharply (-99%), mainly due to a one-off gain in 1H 2024 related to a subsidiary recovery.

• Employee costs and raw material expenses rose with higher headcount and increased activity following the acquisition.

• Total comprehensive loss for 1H 2025 was S$605,000.

• Net asset value per share at 30 June 2025 was negative 0.05 Singapore cents (31 December 2024: negative 0.15 Singapore cents).

• Borrowings reduced from S$2.1 million (end-2024) to S$1.6 million (end-June 2025); cash position diminished to S$160,000.

• The Group operates under material uncertainty regarding going concern, supported by cost-reduction strategies and an undertaking of financial support by a controlling shareholder.

• No dividend declared for the period due to ongoing losses.

• Management expects margin pressure in the clinic from rising supplier costs but is actively seeking new acquisitions and growth opportunities amid macroeconomic uncertainty.